[AACR] A Randomized, Nivolumab-Controlled, Phase II Biomarker Study of Lomvastomig and Tobemstomig in Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus |
|
This post will be closed automatically in 2026-09-01 04:21
Reward25points
|
25
A Randomized, Nivolumab-Controlled, Phase II Biomarker Study of Lomvastomig and Tobemstomig in Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus
50
HSPA6 Confers Lenvatinib Resistance in Hepatocellular Carcinoma by Promoting Phase Separation每Mediated TXNRD1 Stabilization to Suppress Ferroptosis
20
Lipid Nanoparticle每Encapsulated mRNA-2752 Encoding Human OX40L, IL-23, and IL-36污 plus Durvalumab Induces an Immunostimulatory Effect within the Tumor Microenvironment in Patients with Advanced Solid Tumors
30
Abstract 955: LY3200882, a novel, highly selective TGF汕RI small molecule inhibitor
30
FDG-PET每Based Selective Deescalation of Chemoradiation in Human Papillomavirus每Related Oropharyngeal Squamous Cell Carcinoma: A Multicenter Phase II Trial
